IL2 and squamous cell carcinoma: Prior to the immune checkpoint inhibitor era, Stefani et al. reported improved OS and disease free survival utilizing neoadjuvant perilymphatic interleukin 2 (IL-2) in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx [24].